Related Experiment Video
Updated: May 29, 2026
04:14
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution
Published on: April 16, 2019
Glitazones for human nonalcoholic steatohepatitis
Raluca Pais1, Ioana Moraru, Vlad Ratziu
1Université Pierre et Marie Curie, Assistance Publique Hôpitaux de Paris, Hôpital Pitié Salpêtrière, Paris, France.
Therapeutic Advances in Gastroenterology
|September 17, 2011
Summary
Insulin-sensitizing agents, like glitazones, are promising for treating nonalcoholic steatohepatitis (NASH) due to their ability to improve insulin resistance, especially when lifestyle changes are difficult.
Area of Science:
- Hepatology and Endocrinology
- Pharmacology of Metabolic Diseases
Background:
- Nonalcoholic steatohepatitis (NASH) poses a significant health burden due to potential disease progression.
- Long-term adherence to diet and lifestyle modifications for NASH management is often challenging for patients.
- Insulin resistance is a key factor in NASH pathogenesis, making insulin-sensitizing agents a therapeutic consideration.
Purpose of the Study:
- To review the role of glitazones as a pharmacologic therapy for nonalcoholic steatohepatitis (NASH).
- To explore the mechanism of action, therapeutic efficacy, and safety profile of glitazones in NASH patients.
Main Methods:
- Literature review on the use of glitazones in the context of nonalcoholic steatohepatitis (NASH).
- Analysis of existing data regarding insulin resistance correction, treatment effectiveness, and adverse events associated with glitazones.
Main Results:
- Glitazones demonstrate potential in treating NASH by addressing underlying insulin resistance.
- The review synthesizes information on the efficacy and safety of glitazones for NASH management.
Conclusions:
- Insulin-sensitizing agents, specifically glitazones, represent a viable therapeutic avenue for NASH.
- Further investigation into the clinical application of glitazones is warranted, considering their efficacy and safety in NASH.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...